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ABSTRACT Latent and recurrent productive infection of long-living cells, such as neu-
rons, enables alphaherpesviruses to persist in their host populations. Still, the viral factors
involved in these events remain largely obscure. Using a complementation assay in com-
partmented primary peripheral nervous system (PNS) neuronal cultures, we previously
reported that productive replication of axonally delivered genomes is facilitated by pseu-
dorabies virus (PRV) tegument proteins. Here, we sought to unravel the role of tegument
protein UL13 in this escape from silencing. We first constructed four new PRV mutants in
the virulent Becker strain using CRISPR/Cas9-mediated gene replacement: (i) PRV Becker
defective for UL13 expression (PRV DUL13), (ii) PRV where UL13 is fused to eGFP (PRV
UL13-eGFP), and two control viruses (iii and iv) PRV where VP16 is fused with mTurquoise
at either the N terminus (PRV mTurq-VP16) or the C terminus (PRV VP16-mTurq). Live-cell
imaging of PRV capsids showed efficient retrograde transport after axonal infection with
PRV UL13-eGFP, although we did not detect dual-color particles. However, immunofluores-
cence staining of particles in mid-axons indicated that UL13 might be cotransported with
PRV capsids in PNS axons. Superinfecting nerve cell bodies with UV-inactivated PRV
DUL13 failed to efficiently promote escape from genome silencing compared to UV-PRV
wild type and UV-PRV UL13-eGFP superinfection. However, UL13 does not act directly in
the escape from genome silencing, as adeno-associated virus (AAV)-mediated UL13
expression in neuronal cell bodies was not sufficient to provoke escape from genome
silencing. Based on this, we suggest that UL13 may contribute to initiation of productive
infection through phosphorylation of other tegument proteins.
IMPORTANCE Alphaherpesviruses have mastered various strategies to persist in an
immunocompetent host, including the induction of latency and reactivation in periph-
eral nervous system (PNS) ganglia. We recently discovered that the molecular mecha-
nism underlying escape from latency by the alphaherpesvirus pseudorabies virus (PRV)
relies on a structural viral tegument protein. This study aimed at unravelling the role
of tegument protein UL13 in PRV escape from latency. First, we confirmed the use of
CRISPR/Cas9-mediated gene replacement as a versatile tool to modify the PRV ge-
nome. Next, we used our new set of viral mutants and AAV vectors to conclude the
indirect role of UL13 in PRV escape from latency in primary neurons, along with its
spatial localization during retrograde capsid transport in axons. Based on these find-
ings, we speculate that UL13 phosphorylates one or more tegument proteins, thereby
priming these putative proteins to induce escape from genome silencing.
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Alphaherpesviruses, including herpes simplex virus (HSV-1 and -2), varicella zostervirus (VZV), and pseudorabies virus (PRV), are ancient pathogens that have
evolved with their hosts. Over the years, these viruses have developed a remarkable
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way to persist in the host population: a lifelong persistent infection, termed latency
or quiescence, with periodic reactivation, in which the viral genome reenters produc-
tive replication (1). Productive replication occurs after a cascade-dependent process
of viral gene transcription followed by assembly of new progeny virions (2).
Productive replication is often accompanied by pathologies such as oral and genital
ulcerations, dermatomal rash with pain and itching, reproductive disorders like abor-
tion and neonatal disease, or nervous system disorders such as encephalitis (3). As far
as is known, no pathologies are directly associated with the latent infection. A hall-
mark of all alphaherpesviruses is the establishment of latency in peripheral ganglia of
the nervous system (e.g., the trigeminal ganglion) after primary productive infection
in mucosal epithelia. Remarkably, infected neurons do not die, but rather the viral ge-
nome is stably retained in neuronal nuclei in the absence of detectable viral protein
expression, rendering the infection undetectable by the immune system. However,
periodic reactivation and subsequent progeny virion production is essential for effi-
cient transmission of infection to new hosts. Reactivated virions travel back from neu-
ronal cell bodies to mucosae via anterograde axonal transport. Efficient replication in
the epithelium promotes shedding of infectious progeny virions in mucosal secre-
tions, which are available to infect new hosts (1–3).
Despite the crucial role of latency and periodic reactivation in alphaherpesvirus per-
sistence and pathogenesis, the molecular mechanisms underlying these events are not
well understood. Koyuncu et al. (4) recently identified two different mechanisms for
pseudorabies virus (PRV), a swine alphaherpesvirus closely related to HSV-1 and -2, to
escape from latency: (i) a cellular stress-mediated slow route and (ii) a viral tegument-
mediated fast route. The former route involves cellular protein kinase A and c-Jun N-
terminal kinase activity, and has already extensively been studied, while the latter acts
independently from cellular kinases but the mechanism so far remains obscure. These
findings were discovered using an in vitro trichamber model, in which peripheral neu-
ronal cell bodies are physically and fluidically separated from their axonal termini (5).
Administration of a low viral dose in the axonal compartment mimics the natural route
of neuronal invasion by long-distance retrograde axonal transport. This protocol results
in the establishment of a quiescent, reactivatable infection in neuron cell bodies (6).
Interestingly, simultaneous delivery of a high dose of UV-inactivated or nucleocapsid-
deficient PRV particles to nerve cell bodies enabled infectious PRV genomes to escape
from latency after inoculation at the axonal compartment (4). These results implied
that specific viral tegument proteins are required to induce a productive viral infection
in neurons. The researchers ruled out the PRV early protein EP0 and the viral kinase
Us3 (4). However, the exact viral tegument protein or proteins responsible for PRV
escape from genome silencing remain unknown. In this context, HSV-1 tegument pro-
tein UL13 is known to promote viral transcription through alterations in RNA polymer-
ase II phosphorylation (7). UL13 is a serine/threonine kinase conserved throughout all
members of the Herpesviridae (8). Alternatively, this viral kinase might activate specific
cellular pathways or phosphorylate other viral tegument proteins, which in turn may
stimulate viral gene transcription.
The main objective of our study was to pinpoint the role of UL13 in the escape
from PRV genome silencing. Therefore, we constructed a PRV mutant that did not
express UL13, and an adeno-associated virus (AAV) vector expressing UL13 to deter-
mine if UL13 was necessary and sufficient to induce PRV escape from genome silencing
in neurons. In addition, we hypothesized that upon entry of PRV virions into axons, nu-
cleocapsids harboring the viral genome are transported separately from viral tegument
proteins that orchestrate the onset of viral genome transcription. To test this hypothe-
sis, we sought to track UL13 protein transport in axons along with nucleocapsids.
Therefore, we also constructed PRV mutants harboring fluorescently tagged UL13 or
VP16 to track viral protein transport in axons via live-cell imaging. Tegument protein
VP16 is a viral transcription activator that is transported separately from PRV nucleo-
capsids in chicken embryo dorsal root ganglia (DRG) (9). All PRV mutants were
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constructed using CRISPR/Cas9, one of the most powerful and versatile tools for pre-
cise gene editing at this time (10). The traditional approach to construct herpesvirus
mutants involved homologous recombination of DNA fragments with the viral ge-
nome, often introduced as a bacterial artificial chromosome (BAC), which is a slow and
laborious process. Genome engineering with CRISPR/Cas9 relies on a single guide RNA
(sgRNA) that directs an endonuclease (Cas9) toward a specific gene locus due to
sequence homology. The DNA at this locus is cleaved and subsequently “repaired” by
mammalian DNA repair mechanisms that are inherently error-prone, thereby inducing
insertions, deletions and mutations at the target site, potentially knocking out expres-
sion of the specific gene product. Alternatively, foreign genes (e.g., fluorophore genes)
can be knocked-in through homologous recombination in the presence of a DNA do-
nor with homology arms. Using this method, fluorophore-tagged viruses can be pro-
duced to facilitate screening. The CRISPR/Cas9 toolbox has already been exploited for
its gene editing potential in herpesviruses, including herpes simplex virus (HSV), PRV,
and cytomegalovirus (CMV) (11–14). However, the technology of editing functional
PRV genes is still in development.
We first confirmed the use of CRISPR/Cas9 as an effective method to modify the
PRV genome. Following characterization of this newly constructed set of mutants, we
confirmed via live-cell imaging that VP16 is not cotransported with PRV nucleocapsids
during retrograde axonal transport upon viral entry into axons. The fluorescent signal
of UL13-eGFP was too faint for live-cell imaging, but immunofluorescence staining
indicated that UL13 is cotransported with PRV nucleocapsids during retrograde axonal
transport. Finally, we demonstrated that UL13 is indirectly involved in PRV genome
escape from silencing.
RESULTS
CRISPR/Cas9 is an effective tool to edit PRV genomes. Different PRV mutants
were constructed using CRISPR/Cas9-mediated homologous recombination, as shown
schematically in Fig. 1A and B.
The PRV null for UL13 protein expression (PRV DUL13) strain was constructed from
a PRV wild type (WT) Becker strain background by replacing the middle part of the
UL13 coding sequence (CDS) with the eGFP coding sequence. Both ends of the UL13
CDS were left intact, as they overlap those of UL12 and UL14. A UL13-eGFP fusion mu-
tant was constructed in a PRV 180 background. PRV 180 is a virus previously made to
express red-fluorescent capsid to allow for imaging of individual viral particles in living
neurons (15, 16). Enhanced GFP (eGFP) was inserted at position 105 of UL13, as it could
not be fused to the UL13 N or C terminus without polar effects on UL12 and UL14.
Both PRV UL13 mutants were produced in a HEK293T cell line expressing Cas9 and
UL13 sgRNA (Table 1) targeting the inner region of UL13.
VP16 is abundantly present in the PRV tegument and has already been visualized
during transport in axons (9). Accordingly, we fused PRV 180 VP16 to the fluorophore
mTurquoise version 2 (mTurq) to serve as an internal control for transport. The coding
sequence of VP16 and its flanking regions do not overlap those of other proteins and,
thus, mTurquoise v2 could be linked to either the N (mTurq-VP16 PRV180) or C termi-
nus (VP16-mTurq PRV180) of VP16. The former and latter were constructed in HEK293T
monoclonal cell lines stably expressing Cas9 and VP16 sgRNA1 or sgRNA2, respectively
(Fig. 1A).
First, we assessed the efficacy of viral mutant production using homologous recom-
bination induced by CRISPR/Cas9 by comparing the amount of fluorescent virus pro-
duced in control HEK293T cells with monoclonal HEK293T cell lines expressing differ-
ent sgRNAs and Cas9 (Fig. 1C). Although transfection of 10mg of whole PRV genomes
in control HEK293T cells resulted in production of 103 PFU/ml progeny virus, sgRNA/
Cas9-expressing HEK293T cells did not support any detectable viral replication upon
transfection of viral DNA (,10 PFU/ml). In contrast, infection with intact PRV virions
(multiplicity of infection [MOI] of 1) consistently resulted in efficient viral progeny
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production with titers ranging from 106 to 107 PFU/ml in all different cell types. In the
absence of donor plasmids containing the fluorophore flanked by homology arms, no
fluorescent plaques were observed upon assay of progeny virus. However, addition of
donor plasmids, followed by PRV inoculation, resulted in the production of fluoro-
FIG 1 CRISPR/Cas9-mediated mutagenesis of PRV through homology-directed recombineering of the PRV genome. (A) Schematic of UL13 and VP16
targeting and eGFP or mTurq incorporation. (B) Workflow of PRV mutant production. (C) Efficacy of (fluorescent) progeny virus propagation in HEK293T
cells with or without stable expression of sgRNA-Cas9 upon transfection of the whole PRV genome, inoculation by PRV virions, and/or addition of donor
plasmids. Three independent experiments were performed, and data are represented as means 1 standard deviations (SD). Different lower case letters
indicate significant (P, 0.05) differences in the total number of plaques among different experimental conditions. Different upper case letters indicate
significant (P, 0.05) differences in the number of fluorescent plaques among different experimental conditions.
TABLE 1 CRISPR/Cas9 target sequences
Name spCas9 sgRNA+ PAMa
Target sequences
(GenBank JF797219.1)
UL13 sgRNA cgaggccgtcatgacgctgc TGG 77651–77673
VP16 sgRNA 1 gtgcgtggtcgcgttcgacg AGG 9978–10000
VP16 sgRNA 2 acatccggttgagcgcgtcg CGG 11172–11194
aPAM, protospacer adjustment motif; sgRNA, single guide RNA. Lowercase letters represent the spCas9 sgRNA,
and uppercase letters are the PAM sequences.
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phore-harboring progeny viruses with the highest efficacy (.80% of fluorescent pla-
ques) observed for the VP16-mTurq fusion mutant. These results show that CRISPR/
Cas9 is a simple and effective way to produce PRV mutants.
Confirmation of CRISPR/Cas9-constructed PRV mutants. Mutations were con-
firmed through PCR amplification followed by Sanger sequencing, immunofluores-
cence (staining) and Western blot analysis.
First, correct insertion of fluorescent protein genes into the genome of plaque-puri-
fied PRV mutants was analyzed. DNA of purified virus stocks was first subjected to PCR
using region-specific primers (Table 2). Identities were then confirmed by Sanger
sequencing. Next, fluorophore expression was evaluated after infection with different
PRV mutants. Infection of PK15 cells with PRV DUL13 led to significant green fluores-
cence compared to infection with PRV WT (Fig. 2A). PK15 cells infected with double-
tagged PRV 180 UL13-eGFP emitted green fluorescence in addition to red fluorescence,
while PRV 180-infected PK15 cells only emitted red fluorescence (Fig. 2B). Interestingly,
UL13-eGFP mainly accumulated around the nucleus (perinuclear region) of PK15 cells,
as depicted by the magnified image in the lower right corner of Fig. 2B. Likewise, dou-
ble-tagged PRV 180 mTurq-VP16 and PRV 180 VP16-mTurq induced the formation of
double cyan and red fluorescent viral plaques. Viral plaque assays consistently showed
that all viral mutant plaques emitted the correct fluorescent signals, showing there
was no contamination with parental viral strains.
Correct protein expression of different PRV mutants was confirmed by double im-
munofluorescence staining of PK15 cells infected with different PRV viruses, as shown
in Fig. 2C and D. PRV WT-infected PK15 cells clearly expressed UL13, while PRV DUL13-
infected cells did not (Fig. 2C). In Fig. 2D, colocalization analysis in ImageJ of PRV fusion
mutants shows perfect overlap between UL13 and eGFP in PRV UL13-eGFP (upper pan-
els) and between VP16 and mTurquoise in PRV 180 mTurq-VP16 and PRV 180 VP16-
mTurq (lower panels).
Western blot analysis of purified extracellular virions (1012 genome copies) was per-
formed to assess structural incorporation of different proteins into PRV virions.
Staining of major capsid protein VP5 functioned as a loading control to correlate pro-
tein expression to the amount of capsid protein. Analysis of UL13 demonstrated the
absence of UL13 in PRV DUL13, compared to PRV WT (red arrow). As expected, the
UL13-positive band of PRV UL13-GFP had shifted to 675 kDa from6 40 kDa for PRV
180 due to fusion with eGFP (6 27 kDa). The purple arrows indicate a nonspecific band
present in all purified PRV strains. Absence of UL13 kinase activity could result in exces-
sive incorporation of another important viral kinase, Us3. However, equal relative
amounts of Us3 were present between PRV WT and PRV DUL13 strains when normal-
ized to the major capsid protein VP5. While VP16 expressed from PRV WT and from
PRV DUL13 was present as a single protein band, VP16 of PRV 180 and PRV 180 UL13-
eGFP was present as a double band. This intriguing phenomenon was also apparent
on gel electrophoresis of PCR-amplified products of the VP16 region of the respective
viruses (Fig. 2E and primers are shown in Table 2). This suggests that during production
of PRV 180, mutations such as duplications occurred in the PRV 180 genome, resulting
in multiple gene transcripts and thus protein bands. For VP16 of PRV 180 VP16-mTurq
and PRV 180 mTurq-VP16 virions, a triple band was documented. The upper band of
675 kDa corresponds to the fusion protein consisting of VP16 (6 50 kDa) and
mTurquoise (6 27 kDa).
TABLE 2 Primers for qPCR and sequencing
Name Forward (59–39) Reverse (59–39)
UL13 seq gacgacgcggccgcgctcgacgaggac ctcgacgagcaggtcgtgcacgtac
VP16 seq ggacgagagcacccccgggcggaag ccgcgtcgctcatggtggtcgctg
UL54 qPCR tgcagctacaccctcgtcc tcaaaacaggtggttgcagtaaa
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Characterization of CRISPR/Cas9-constructed PRV mutant infection in PK15
cells and dissociated superior cervical-ganglion (SCG) neurons. Virus plaque forma-
tion was assessed in PK15 cells by standardizing the inoculum at 106 genome copy
numbers per PRV mutant (Fig. 3A). Deletion of UL13 in PRV WT resulted in a significant
reduction of 82.76 0.3% in viral plaque formation, showing that PRV DUL13 is less ca-
pable of infecting PK15 cells. In addition, the average size of PRV DUL13 plaques was
significantly smaller (7426 135mm) compared to that of PRV WT (9586 166mm), pin-
pointing the importance of UL13 in viral spread. Although in a plaque assay comparing
stocks with equivalent numbers of genomes, PRV 180 formed significantly fewer pla-
ques compared to PRV WT, no significant difference was observed in the number of
plaques or plaque diameters between PK15 cells inoculated with different PRV 180 or
different PRV 180 fusion mutants. This indicates that UL13 or VP16 fusion proteins do
not interfere with the ability of PRV virions to infect PK15 cells.
Kinetics of viral protein expression and virus propagation were assessed in PK15 cells
by standardizing the inoculum at an MOI of 1. As shown in the Fig. 3B, all viral mutants
grew less well compared to PRV WT, as shown in the reduction of virus titers. However,
between PRV 180 and different PRV 180 fusion mutants, no overall significant difference
was observed in viral titers. Temporal expression of IE180, Us3, gB, or VP26 did not signif-
icantly differ between the parental strains and different viral mutants (Fig. 3C). Except for
PRV DUL13, which lacked UL13 expression, all viruses started expressing UL13 at similar
time points. The number of cells expressing VP16 did not differ between parental strains
(PRV WT and PRV 180) and their derivatives (PRV DUL13 and PRV 180 UL13-eGFP, PRV
180 mTurq-VP16, or PRV 180 VP16-mTurq, respectively). However, all PRV 180 strains had
a lower percentage of VP16-positive cells between 3 and 9 h postinfection (hpi) com-
pared to PRV WT and PRV DUL13, which might reflect mutations in the genome of PRV
180, as suggested by the multiple VP16 transcripts and proteins expressed by PRV 180
compared to PRV WT. Finally, we evaluated infection of dissociated superior cervical gan-
glia (SCG) neurons by different PRV mutants. No significant difference was observed
among different viruses upon infection at MOI 1. Indeed, all neurons were positive for
IE180 at 3 hpi and at 9 hpi, and all neurons expressed PRV late proteins UL13, VP16, and
VP26. Still, no virus replication was observed in dissociated SCG neurons, as viral titers in
cell supernatant remained undetectable.
Since there were no significant differences in the different infectivity parameters
between N- or C-terminal tagged mTurq-labeled VP16 PRV 180 mutants, further experi-
ments were conducted with the N-terminal variant only.
UL13, but not VP16, is cotransported with PRV capsids in SCG neurons. Our
newly constructed collection of dual fluorescent PRV mutants was used to track PRV
capsids along with tegument proteins UL13 or VP16 during live axonal transport in
chambered SCG neurons. To determine suitability of mutants in live-cell imaging, puri-
fied virus particles were first spotted onto coverslips and fluorescence was verified. We
observed red as well as cyan fluorescent puncta in the PRV 180 mTurq-VP16 stock, but
were unable to detect green fluorescent puncta in the PRV 180 UL13-eGFP stock (Fig. 4,
upper panel). This result suggests that the amount of UL13-eGFP by itself was likely too
low to emit detectable levels of green fluorescence. However, immunofluorescence
staining of eGFP confirmed that 82% of monomer red fluorescent protein (mRFP1)-cap-
sid-containing particles had incorporated UL13-eGFP (Fig. 4, middle panel). In the
mTurq-VP16 virus stock, 76% of red puncta colocalized with cyan puncta, suggesting
that the majority of mRFP1-capsid-containing particles in the virus stock had incorpo-
rated detectable mTurq-VP16 (Fig. 4, lower panel).
Next, we performed live-cell imaging of moving virus particles in SCG axons.
Starting from 30min after inoculation in the N compartment, mRFP1-labeled capsids
of PRV 180 dual fluorescent strains were readily detected moving in a retrograde direc-
tion (i.e., toward the cell bodies) in SCG axons with dynamics similar to that of mono
fluorescent PRV 180. Indeed, there was no significant difference in the percentage of
moving capsids between PRV 180 (79.296 7.00%), PRV 180 UL13-eGFP (72.676 8.55%),
and PRV 180 mTurq-VP16 (73.346 10.87%) (pie charts in Fig. 5A). Further, the average
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FIG 2 Characterization of newly constructed PRV mutants. All scale bars represent 100mm. (A) Fluorescence microscopy images of PRV wild type (WT) and
PRV DUL13 plaques in PK15 cells. (B) Fluorescence microscopy images of PRV 180, PRV 180 UL13-eGFP, PRV 180 mTurq-VP16, and PRV 180 VP16-mTurq
plaques in PK15 cells. Magnified images (3) of the green or blue channels are shown in the lower right corner of the respective images. (C) Absence of
UL13 in PRV DUL13 was confirmed by immunofluorescence staining using polyclonal rabbit anti-UL13 antibodies. (D) Colocalization of eGFP with UL13 and
mTurq with VP16 in PRV 180 UL13-eGFP and PRV 180 mTurq-VP16 or PRV 180 VP16-mTurq, respectively, as confirmed by immunofluorescence staining
using polyclonal rabbit anti-UL13 or -VP16 antibodies. (E) Western blot analysis of purified progeny virions (upper image). Agarose gel electrophoresis of
VP16 gene PCR products of different PRV strains (lower image).
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velocity of capsid transport did not significantly differ between PRV 180 (1.176 0.55mm/
s), PRV 180 UL13-eGFP (1.076 0.48mm/s), and PRV 180 mTurq-VP16 (1.146 0.42mm/s), as
shown in Movie S1 to S3 in the supplemental material and the graph in Fig. 5A. These find-
ings show that tagging UL13 or VP16 with a fluorophore does not influence transport dy-
namics of mRFP1-capsids of PRV 180. During retrograde transport, only 4.346 3.22% of
moving PRV 180 mTurq-VP16 capsids (red) emitted cyan fluorescence, while the majority
of stationary particles (78.416 6.98%) emitted red as well as cyan fluorescence.
Live-cell imaging of UL13 was not possible due to low green fluorescence emission.
Therefore, axons in both the M and N compartments were fixed at 2 hpi and stained for
eGFP to track UL13 localization (Fig. 5B). It should be noted that fixation caused a decrease
FIG 3 Viral infectivity, spread, and propagation parameters of newly constructed PRV mutants in PK15 cells. (A) Total number of plaques (left) and average
plaque diameter (right) were determined 48 hpi upon standardizing the inoculum at 106 genome copies. Experiments were performed in triplicate. Data
are represented as means1 SD and different lower case letters indicate significant (P, 0.05) differences between different viral mutants. (B) Temporal virus
propagation was determined on PK15 cells by standardizing the inoculum at an MOI of 1. Significant differences are indicated by asterisks: ***, P, 0.001.
(C) Expression kinetics of different viral proteins were determined on PK15 cells by immunofluorescence staining using antibodies against IE180 (immediate
early protein), UL13 (viral kinase and tegument protein), Us3 (viral kinase and tegument protein), VP16 (tegument protein), gB (envelope protein), and VP26
(capsid protein). Experiments were performed in triplicate. Significant differences are indicated by asterisks: **, P, 0.01; ***, P, 0.001.
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in mRFP fluorescence and made it impossible to directly stain UL13 using our polyclonal
rabbit serum. Still, staining eGFP enabled us to detect UL13-eGFP. Interestingly, the per-
centage of red capsid puncta colocalizing with green puncta was similar in the N compart-
ment (75.516 8.77%) as in the M compartment (80.696 11.57%). These data indicate that
UL13 is cotransported with PRV capsids during retrograde transport, while VP16 stays
behind upon infection of neuronal axons.
UL13 is involved indirectly in PRV escape from genome silencing in SCG
neurons. Using a trichamber neuron culture system, we previously showed that deliv-
ery of a high dose of UV-treated or nucleocapsid-deficient PRV light (L) particles to
neuronal cell bodies triggers escape from silencing of infectious PRV viruses applied to
axons, suggesting that tegument proteins might be involved (4). To understand
whether the viral kinase tegument protein UL13 plays a role, we applied 1010 genome
copies of UV-inactivated PRV DUL13 virions to neuron cell bodies, while simultaneously
inoculating axons with a low dose (102.5 PFU) of red capsid-labeled PRV 180 (Fig. 6A).
Dioctadecyloxacarbocyanine perchlorate (DiO) was added to the N compartment to
identify neuronal cell bodies with axons that penetrate into the N compartment. Phase
and fluorescent images are shown in Fig. 6B. As expected, 86.36 13.6% of DiO-positive
(i.e., connected with the N-compartment) neurons produced red fluorescence, corre-
sponding to mRFP1-capsid proteins, 4 days after treatment with UV-inactivated PRV
WT virions (Fig. 6C). This percentage was significantly (P, 0.05) higher compared to
mock treatment (2.56 3.8%) or treatment with UV-inactivated PRV DUL13 (5.36 8.3%).
Interestingly, we observed similar results when standardizing the inoculum of UV-inac-
tivated viruses for PFU (105 PFU), even though neuronal cell bodies are flooded with
defective viral particles delivering virion proteins in the case of UV-inactivated PRV
DUL13 compared to PRV WT. Fusion of UL13 to eGFP did not influence its function in
escape from genome silencing, as indicated by the high percentage of connecting
neurons that escaped from silencing upon treatment with UV-inactivated PRV 180
UL13-eGFP (88.06 13.3%).
To confirm the role of UL13 in PRV escape from genome silencing, we produced
AAVs that induce the expression of UL13 and reporter protein eGFP linked by self-
cleavable p2a in SCG neurons. AAVs expressing only p2a and eGFP functioned as con-
trols. Neuronal cell bodies started to express eGFP at 2 to 3 dpi by AAVs, which accu-
mulated over the following days. SCG neurons clearly express UL13 at 6 dpi with AAV-
FIG 4 Validation of PRV 180 UL13-eGFP and PRV 180 mTurq-VP16 for live-cell imaging. Red particles (mRFP1-
capsid) from purified viral stocks were analyzed for green (PRV 180 UL13-eGFP) and cyan (PRV 180 mTurq-
VP16) fluorescence emission. PRV 180 UL13-eGFP particles were additionally stained with polyclonal rabbit anti-
eGFP antibodies. Pie charts show the proportion of virions with structurally incorporated UL13 or VP16 (dual
fluorescent) to capsids without UL13 or VP16 incorporation (mono fluorescent). Scale bars represent 10mm.
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UL13, as demonstrated by immunofluorescence staining in Fig. 7A. Expression of UL13
did not influence cell viability, as analyzed using ReadyProbes cell viability imaging kit
(Thermo Fisher Scientific). In contrast to UV-inactivated PRV WT, UL13-expressing neu-
rons were not sufficient to facilitate PRV 180 genomes to escape from silencing after
inoculation of axons (Fig. 7B and C). Instead, only 3.66 4.2% of connecting neurons
produced mRFP1-labeled capsid proteins in the presence of UL13 expression at 4 dpi,
showing that UL13 does not play a direct role in the escape from genome silencing by
PRV. Similarly, expression of eGFP or mock treatment of neurons did not induce escape
from genome silencing by PRV. Together, these data show that UL13 plays an indirect
role in the escape from genome silencing by PRV.
DISCUSSION
Induction and escape from viral genome silencing in peripheral nervous system
(PNS) neurons is a hallmark of alphaherpesvirus biology. The double-stranded DNA
(dsDNA) from incoming virions either rapidly associates with histones, resulting in ge-
nome silencing, or is bound by RNA polymerase II to initiate the orderly cascade of viral
gene transcription followed by virion production. Still, the exact molecular events that
determine the fate of these incoming viral genomes are poorly understood. Using a
compartmented complementation assay in trichambers, Koyuncu et al. (4) identified a
new distinct molecular mechanism to start productive infection from quiescently des-
tined PRV genomes: a rapid viral tegument-mediated route. For example, complement-
ing neuronal cell bodies infected with UV-inactivated whole virions or light particles
(containing tegument proteins but lacking nucleocapsids) facilitates productive axonal
PRV 180 infection that was destined to be silenced. In the current study, we sought to
identify the role of the viral kinase and tegument protein UL13 in the escape from
PRV genome silencing in SCG neurons. This study required the construction of new
PRV mutants. Although some PRV DUL13 mutants have been constructed in other PRV
backgrounds, no PRV Becker DUL13 mutants without any other modifications had
been constructed (16, 17). As the Becker strain efficiently induces escape from genome
silencing, we constructed a UL13-deletion mutant in the PRV Becker background.
Further, we also used the Becker mutant PRV 180 (which encodes the VP26-mRFP1
fusion protein that is incorporated into capsids) to construct mutants with UL13 fused
to enhanced green fluorescence protein (eGFP). We also replaced the VP16 coding
sequence with a hybrid gene encoding a fusion protein with VP16 fused to
mTurquoise v2 (mTurq) as an internal control. We showed that homologous recombi-
nation-mediated gene replacement was highly efficient upon sgRNA/Cas9-nicking of
target PRV DNA. Indeed, up to 83% of all progeny viruses formed fluorophore-positive
plaques. This percentage is similar or even higher than previously described for the
construction of PRV mutants through CRISPR/Cas9 (11, 12). However, these published
studies did not screen selected sgRNAs for potential off-target effects. Nonspecific
binding of sgRNAs to genomic regions outside the target sequence can result in
unwanted mutations in these genes (18). Therefore, we used the CRISPOR algorithm to
select sgRNAs without any potential off-target effects in the PRV genome (19).
Disruption of UL13 clearly reduced production of infectious virus, as PRV DUL13
produced a 10-fold lower viral titer compared to PRV WT at 18 hpi. This decrease was
comparable to that previously reported for two PRV mutants carrying UL13 deletions
(16, 20). Also, the infectivity and spread of PRV DUL13 in PK15 cells was decreased
compared to PRV WT, as PRV DUL13 produced about 10-fold fewer plaques that were
on average 1.5-fold smaller in diameter compared to PRV WT. This phenomenon has al-
ready been described for other alphaherpesviruses, such as HSV-1 lacking UL13 (21). It
was suggested that HSV-1 tegument uncoating might be affected in the absence of
UL13 through lack of phosphorylation of viral components, actin, or other cytoskeletal
elements (22). In addition, HSV-2 UL13 was proposed to regulate nuclear egress by
localized disruption of nuclear lamins (23). The latter hypothesis is consistent with the
perinuclear localization we observed for UL13, but especially for the fusion protein
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UL13-eGFP. These data indicate that during virus propagation, UL13 accumulates close
to nuclear lamins and might be involved in nuclear egress of PRV. In the absence of
UL13, nuclear egress of PRV and thus virus propagation might be affected. Still, the
exact role of UL13 in the infectivity and spread of PRV remains enigmatic.
FIG 5 Axonal transport of UL13 and VP16 in compartmented SCG neurons. All scale bars represent 10mm.
(A) Live-cell imaging of PRV 180, PRV 180 UL13-eGFP, and PRV 180 mTurq-VP16 retrograde transport (see
also Movie S1 to S3 in the supplemental material). Images show the merge of red, green, and phase of a
Movie snapshot. Pie charts show the proportion of moving mono or dual fluorescent capsids to mono or
dual fluorescent stationary capsids. Capsid velocities are given in the graph. Experiments were performed in
triplicate. Different lower case letters represent significant differences (P, 0.05). (B) Immunofluorescence
staining of eGFP in M (left) and N (right) compartment 2 hpi to track UL13 transport in combination with
capsid transport. Pie charts show the proportion of dual fluorescent capsids to mono fluorescent capsids.
Arrows and arrowheads point at mono and dual fluorescent capsids, respectively.
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As described for HSV-1 strain KVP26mRFP1 expressing a VP26 fusion with mRFP, the
replication of PRV 180 was decreased compared to the parental strain. This difference
might be caused by the steric hindrance of mRFP or by a destabilization effect of fusion
capsid proteins during capsid formation. However, unlike disrupting UL13, fusing the
kinase to eGFP did not affect virus propagation kinetics, infectivity, or spread. Indeed,
the viral titers, number of plaques, and plaque diameters of PRV 180 UL13-eGFP did
not significantly differ from those of its parental strain, PRV 180. These data also sug-
gest that tagging UL13 with eGFP does not influence its (kinase) activity, as PRV DUL13
induced smaller plaques, while PRV UL13-eGFP did not. The fact that PRV UL13-eGFP
was still able to induce escape from silencing by PRV virions destined for quiescence,
while PRV DUL13 was not, corroborates this hypothesis. Similarly, fusing mTurq to the
N- or C-terminal end of VP16 did not decrease its infectivity, as described previously
(9). Finally, fusing UL13 to eGFP did not affect velocities of capsid trafficking in SCG
axons, as capsid transport velocities were similar for all fusion mutants and the
FIG 6 UL13 is important in the escape from genome silencing by PRV. (A) Schematic of complementation assay
used to study escape from genome silencing in chambered SCG neurons. (B) Phase, fluorescent, and merged
images of S compartments at 4 dpi using different stimuli in the S compartment. Dioctadecyloxacarbocyanine
perchlorate (DiO) was added to the N compartment to visualize the number of neurons with N compartment-
penetrating axons. Scale bars represent 1,000mm. (C) The percentage of PRV capsid-positive neurons among the
total number of neurons with N compartment-penetrating axons. Experiments were performed 5 times. Data are
shown as means 1 SD and significant differences (P, 0.05) are indicated by different lower case letters.
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parental virus. These velocities of capsid transport also corresponded to those previ-
ously published for PRV 180 in chicken embryo dorsal root ganglion neurons (DRGs)
(9).
Further, our initial hypothesis was that during retrograde viral transport in axons,
UL13 moves separately from PRV nucleocapsids, similar to what was described for
VP16 (9). In our hypothesis, PRV capsids would arrive at the nuclear pore before UL13,
preventing the tegument kinase from activating PRV genome transcription and thus
favoring UL13 quiescence. However, we observed that while VP16 separates from cap-
sids and stays behind upon axonal inoculation of SCG neuronal axons, at least some
UL13 copies are cotransported with capsids during retrograde transport in axons.
Although we were unable to track live transport of UL13 using eGFP fluorescence, we
were able to detect UL13-eGFP by immunofluorescence staining. In this way we observed
that red capsids arriving in the M compartment still contain UL13-eGFP. We were unable
to visualize UL13-eGFP directly with antibodies to UL13, presumably because of the small
amount of UL13 incorporated in the virion. Indeed, even mass spectrometry was not sensi-
tive enough to detect UL13 in PRV virions (24). Still, Western blot and immunofluorescence
FIG 7 UL13 is not directly involved in the escape from genome silencing by PRV. (A) SCG neuronal bodies
express eGFP and/or UL13 at 6 days upon inoculation by AAV vectors. (B) Phase, fluorescent, and merged
images of S compartments at 4 dpi following AAV-induced UL13/eGFP expression in the S compartment. Scale
bars represent 1,000mm. (C) The percentage of PRV capsid-positive neurons among the total number of
neurons. Experiments were performed 5 times. Data are shown as mean 1 SD and significant differences
(P, 0.05) are indicated by different lower case letters.
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staining of purified PRV virions demonstrated that UL13 is structurally incorporated into
PRV virions. As a kinase enzyme, UL13 can be reused in multiple cycles, which may explain
why low concentrations of UL13 are incorporated into virions. Similarly, Us3, another im-
portant serine/threonine-protein kinase, is also cotransported with PRV capsids during ret-
rograde axonal infection (9). It was suggested that these viral kinases might facilitate PRV
capsid transport by stabilizing membrane-capsid and microtubule-capsid interactions.
The fact that UL13 is cotransported with PRV capsids does not exclude its function
in escape from genome silencing by PRV. Indeed, we demonstrated that escape from
genome silencing indirectly requires viral tegument protein UL13. Following infection
of neuronal cell bodies with UV-inactivated PRV virions devoid of UL13, axonal PRV 180
infection was silenced. In contrast, cell body infections with UV-inactivated PRV wild
type virions enabled a productive infection by axonally transported PRV 180 particles.
However, UL13 alone expressed in cell bodies from AAV vectors was not sufficient to
induce PRV genome silencing. It should be noted that we were technically unable to
verify the kinase activity of AAV-expressed UL13, as no such tests were then readily
available. Still, our findings from the compartmentalization assays and cotransport
analyses suggest that UL13 is involved in PRV escape from genome silencing through
indirect mechanisms. We propose that another viral tegument protein, yet to be identi-
fied, primes SCG neurons for productive axonal infection upon phosphorylation by
UL13. In the absence of UL13, this tegument protein is not phosphorylated and thus
remains inactive. For HSV, UL13 has been suggested to phosphorylate glycoprotein E
and I, UL41, Us3, ICP0, VP22, and ICP22 (22, 25–30). Glycoproteins E and I are embed-
ded in the viral envelope and likely remain at the plasma and/or endocytic membranes
during virion entry. UL41 is a virion host shutoff endoribonuclease with no apparent
effect on viral gene transcription, and the role of Us3 and EP0 (orthologue of HSV ICP0)
in PRV escape from silencing have already been ruled out (4, 31). Therefore, these pro-
teins are unlikely to facilitate productive PRV infection in the compartmentalization
assay. In contrast, tegument proteins VP22 and ICP22 are interesting candidates for fur-
ther research. Major tegument protein VP22 of HSV-1 inhibits nucleosome deposition
on DNA by binding to TAF-I (template-activating factor I) and thereby activates viral
gene transcription (32). It may be that nonphosphorylated PRV VP22 is unable to in-
hibit nucleosome deposition on incoming PRV genomes and, thus, trigger escape from
silencing. PRV ICP22 is a tegument protein important for proper PRV gene expression
(33). Interestingly, HSV-1 ICP22 is extensively phosphorylated and mediates, in con-
junction with UL13, the phosphorylation of RNA polymerase II (7, 30, 34). Perhaps this
interplay between UL13 and ICP22 is also necessary to induce escape from silencing.
Finally, it is also possible that multiple proteins need to be activated by UL13 phospho-
rylation in order to prevent genome silencing. Alternatively, UL13 might act in parallel
with another tegument protein and both might be required for efficient escape from
genome silencing. Future studies, including the addition of UV-inactivated PRV DUL13
to AAV-UL13 transduced cell bodies in trans and characterization of viral protein phos-
phorylation profiles, will help to uncover the role of these tegument proteins.
In this report, we used CRISPR/Cas9-constructed PRV mutants and complementing
AAV transduction to show that UL13 is indirectly involved in PRV escape from genome
silencing in neurons. Accordingly, it may act through phosphorylation of other tegu-
ment proteins (e.g., VP22 or ICP22). Further, we showed that, unlike VP16, UL13
remains with PRV capsids after axonal entry and may mediate interactions between
PRV capsids and cellular microtubules or membranes. These new insights in alphaher-
pesvirus escape from quiescence will forward the development of efficient antiviral
therapies, a significant aspect of medical research on herpesvirus-induced diseases.
MATERIALS ANDMETHODS
Cells. Cell lines. Porcine kidney epithelial cells (PK15; ATCC, Manassas, VA, USA) were used to pro-
duce and titer PRV stocks. Human embryonic kidney cells expressing large T antigen (HEK293T cells;
ATCC) were used to produce CRISPR lentiviruses, PRV mutants, and adeno-associated viruses (AAVs). All
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cells were maintained in Dulbecco's modified Eagle medium (DMEM) supplemented with 10% fetal bo-
vine serum (FBS), 1% penicillin, and streptomycin (DMEM complete medium).
Primary neurons. Superior cervical ganglia (SCGs) were isolated from embryonic day 17 Sprague-
Dawley rat embryos (Hilltop Labs, Scottdale, PA, USA) as previously described (35). SCG neurons were
cultivated either dissociated in plain dishes or compartmented in trichamber-mounted dishes. Plastic tis-
sue culture dishes (35mm, Falcon) or optical plastic dishes (Ibidi) were coated with 500mg/ml of poly-
DL-ornithine (Sigma-Aldrich, St. Louis, MO, USA) and 10mg/ml of natural mouse laminin (Invitrogen).
Trichambers were installed onto these dishes for compartmentation of neurons and axons as previously
described (5). Neurons were cultured for a minimum of 4weeks prior to experiments.
Viruses. PRV Becker is a wild-type (PRV WT) strain commonly used as background for PRV mutants
(36). PRV 180 expresses a monomeric red fluorescent protein (mRFP)-VP26 fusion protein in a PRV
Becker background (15). PRV DUL13, PRV 180 eGFP-UL13, PRV 180 mTurq-VP16, and PRV 180 VP16-
mTurq viruses were constructed using CRISPR/Cas9-mediated gene replacement, as described below.
Plasmids and sgRNA selection. Synthesized oligonucleotide primers (Integrated DNA Technologies,
Coralville, IA, USA) corresponding to separate targets were cloned into an EspI-digested (New England
BioLabs [NEB], Ipswich, MA, USA) LentiCRISPR v2 plasmid (gift from Feng Zhang; Addgene plasmid num-
ber 52961). Guide sequences were selected using CRISPOR by containing minimal mismatches to any
human or PRV genomic sequences, while maximizing the presumable on-target effect (37). Selected tar-
get sites and protospacer adjustment motif (PAM) sequences are shown in Table 1. There were no
potential off-target regions in the PRV genome, as determined using CRISPOR (http://crispor.tefor.net/)
(19).
Donor plasmids were constructed using the HiFi DNA assembly method (NEB), as described below.
All donor plasmids consisted of a pcDNA3-eGFP backbone (gift from Doug Golenbock; Addgene plasmid
number 13031) with an upfront and downstream homology arm with eGFP or mTurquoise in between
(Fig. 1B). Each set consisted of four fragments, which were PCR-amplified from purified PRV DNA (homol-
ogy arms), pcDNA3-eGFP (vector backbone and eGFP), or pcDNA3-mTurq (mTurquoise v2) using Q5
high-fidelity polymerase (NEB) and specific primer pairs shown in Table 3 (Integrated DNA
Technologies). Silent mutations (underlined) were introduced in PAM sequences of PRV 180 fusion
mutants.
The backbones of AAV plasmids (CMV-eGFP-p2a-WPRE-SV40pA or CMV-eGFP-p2a-UL13-WPRE-
SV40pA) were generated by cloning. Purified viral DNA, a pAAV-mTurq-p2a-WPRE-SV40pA (Engel lab)
and pcDNA-eGFP vector were modified by PCR and assembled using HiFi DNA assembly (NEB). Specific
fragments and primer pairs are shown in Table 3.
Lentivirus production and transduction. Lentiviruses were produced in HEK293T cells by cotrans-
fecting LentiCRISPRv2 plasmids containing separate targets with packaging plasmids pMD2.G and
psPAX2 using polyethylenimine (PEI) reagent (VWR International, Radnor, PA, USA) at a DNA:PEI ratio of
1:3 (wt/wt) following a chloroquine hydrochloride (25mM; Sigma-Aldrich) preincubation step. Fifty-six
hours posttransfection, the cell supernatant was collected, centrifuged at 900  g, clarified by passing
through a 0.45-mm polyethersulfone (PES) filter, and stored at –80°C. Lentiviral titers were determined
using the QuickTiter lentivirus titer kit according to the manufacturer’s instructions (Cell Biolabs, San
Diego, CA, USA).
Fresh HEK293T cells were transduced for 48 h with CRISPR lentiviruses at an MOI of 2.5 in the pres-
ence of 10mg/ml polybrene (Sigma-Aldrich). After 48 h, medium was replaced daily by fresh DMEM me-
dium containing 10mg/ml puromycin for 5 days. Stably transfected cells were then expanded and main-
tained in DMEM medium containing 5mg/ml puromycin. Monoclonal cell lines (HEK293T-UL13sgRNA,
HEK293T-VP16sgRNA1, and HEK293T-VP16sgRNA2) were generated by limiting dilution in order to main-
tain a stable expression of sgRNAs and Cas9. Briefly, 100 ml of a cell suspension of 5 cells/ml was seeded
into each well of a 96-well plate. After 7 days of incubation, the wells were visually inspected for colony
formation. Wells harboring only 1 colony were selected, while those without any or with 2 or more colo-
nies were discarded. After full expansion, Cas9 expression was evaluated using the Cas9 enzyme-linked
immunosorbent assay (ELISA) kit of Cell Biolabs according to the manufacturer’s instructions.
Monoclonal cell lines expressing between 150 and 200 ng/ml Cas9 were selected for downstream
experiments.
Adeno-associated virus production. AAV plasmids containing either CMV-eGFP-p2a-WPRE-SV40pA
or CMV-eGFP-p2a-UL13-WPRE-SV40pA were packaged into AAV-PHP.eB capsids (gift from Viviana
Gradinaru, Addgene plasmid number 103005) at the Princeton Neuroscience Institute Viral Core Facility
(38). AAV particles were purified by iodixanol step gradient followed by column ultrafiltration as previ-
ously described (39, 40). Infectious viral genomes were measured by Taq-Man quantitative PCR (qPCR).
CRISPR/Cas9-mediated gene editing. HEK293T-UL13sgRNA, HEK293T-VP16sgRNA1, and HEK293T-
VP16sgRNA2 cells were pretreated with chloroquine hydrochloride prior to transfection with mock plas-
mids or donor plasmids using PEI reagent as described above. After 24 h, cells were inoculated with ei-
ther mock, PRV WT, or PRV 180 at an MOI of 1. Cells were further maintained in DMEM complete medium
supplemented with 10mM SCR7 and 10mM RS-1 (Sigma-Aldrich) to inhibit nonhomologous end joining
and enhance homologous recombination, respectively. Forty-eight hours postinoculation, cells and su-
pernatant were harvested, pooled, and stored at –80°C. Viral stocks were titrated on PK15 cells using
classic plaque assay and screened for eGFP or mTurquoise expression by immunofluorescence micros-
copy. Fluorescent plaques were subjected to 3 rounds of plaque purification before propagating viral
stocks on PK15 cells.
Quantitative PCR analysis and sequencing. Viral DNA was purified from different PRV stocks
using the QIAamp MinElute virus spin kit (Qiagen, Hilden, Germany) according to the manufacturer’s
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instructions. UL13 and VP16 gene regions were amplified using primer pairs UL13 seq and VP16 seq
(Table 2) using Q5 high fidelity polymerase (NEB) in the presence of 4% dimethyl sulfoxide (DMSO)
(Sigma-Aldrich) and 2.5 M betaine (Sigma-Aldrich). Sequences were confirmed by Sanger sequencing
(Genewiz, South Plainfield, NJ, USA).
Genome copies per ml were determined for each virus stock by means of quantitative PCR (qPCR).
Virus stocks were first treated with 100 U of DNase I for 30min at 37°C (Thermo Fisher) followed by inac-
tivation for 10min at 80°C. Samples were then digested with proteinase K (NEB) in 0.5% Tween 20 for
60min at 55°C, followed by inactivation for 10min at 95°C. Viral genomic DNA was quantified using
UL54-specific primers (Table 2), as previously published (41). A serial dilution of purified whole genome
of PRV Becker virions functioned as a standard. Triplicate reaction mixtures were prepared using a KAPA
SYBR FAST qPCR kit (Sigma-Aldrich). Each experiment was performed in duplicates. The qPCR was per-
formed with an Eppendorf RealPlex Mastercycler with the following amplification conditions: preincuba-
tion at 95° for 2min with 40 cycles of denaturation (5 s at 95°C), annealing (20 s at 55°C), and extension
(10 s at 72°C). The threshold cycle (CT) values were calculated using Mastercycler EP RealPlex 2.2 soft-
ware. Sample CT values were plotted against standard dilution values to determine exact genomic DNA
concentrations. Finally, DNA concentrations were converted into viral genome copies/ml based on the
total PRV genome size (141,113 bp).
Virus purification. Culture supernatants of PRV-infected PK15 cells were clarified by centrifugation
at 40,000  g for 30min at 4°C. The virion pellet was pooled onto a discontinuous OptiPrep gradient
(Sigma-Aldrich) containing 10 to 30% (wt/vol) of iodixanol and centrifuged at 100,000  g for 2.5 h at
4°C. After centrifugation, purified opalescent virion bands were harvested at the interface of the 15%
and 20% layers. Virion bands were pooled in HNE buffer (5mM HEPES, 150mM NaCl, 0.1mM EDTA, pH
7.4) by the use of a 50K filter device (Millipore Corporation, Bedford, MA, USA).
Compartmented complementation assay in primary neurons. SCG neurons were infected by add-
ing a low MOI (102.5 PFU) PRV 180 to the axonal (N) compartment to enable genome silencing after axo-
nal transport. UV-inactivated PRV WT or mutants (1010 genome copies ;105–6 PFU) were added at the
same time into the S compartment. We chose to standardize for genome copies instead of PFU, as PRV
mutant stocks might contain more noninfectious virus particles compared to PRV WT. These defective
particles might still be capable of delivering their content (e.g., tegument proteins) to neurons, thereby
biasing the results. AAVs were added 3 days prior to PRV inoculation to ensure stable UL13 and/or eGFP
expression, but no overexpression, prior to inoculation.
Virus plaque assay. PK15 cells were grown to confluence in 6-well dishes prior to inoculation with
106 genome copies (;10 to 100 PFU) of PRV WT or PRV mutants for 1 h at 37°C. Next, cells were covered
with a solution containing 50% 2 MEM (Thermo Fisher Scientific) and 50% 1.88% carboxymethylcellu-
lose (Sigma-Aldrich). Forty-eight hours postinoculation (hpi), medium was removed, and cells were fixed
in ice-cold methanol for 20min at 220°C. To visualize virus plaques and/or single infected cells, viral im-
mediate early (IE) 180 protein was stained for immunofluorescence as described below using a rabbit
polyclonal anti-IE180 protein antibody and Alexa Fluor 488-conjugated goat anti-rabbit antibodies (42).
Viral growth kinetics. PK15 cells were grown to confluence in 24-well dishes and dissociated SCGs
were cultivated for 4weeks on optical plastic dishes prior to inoculation. Cells were inoculated with PRV
WT or mutants at an MOI of 1 for 1 h at 37°C. Next, cells were briefly exposed to 40mM citrate buffer
(pH 3) to inactivate any free virus particles left from the inoculum that had not infected. After 3 washing
steps with DMEM, cells were further incubated with complete medium at 37°C. At the indicated time
points, supernatants were collected for virus titration and cells were fixed in ice-cold methanol (20min
at220°C) for immunofluorescence staining.
Virus titration. PRV titrations were conducted on PK15 cells, which were incubated at 37°C for
7 days. Titers were expressed as 50% tissue culture infective dose (TCID50).
Immunofluorescence staining. Purified virus particles. For immunofluorescence staining of puri-
fied virus particles, 1 ml of purified virus stocks was spotted onto glass coverslips and left to adsorb to
the glass for 15min at 37°C. Particles were permeabilized in 0.1% Triton X-100 followed by 1 h staining
at 37°C with primary antibodies (rabbit anti-UL13 antibody, produced in-house, rabbit anti-VP16 anti-
body, produced by GenScript [Piscataway, NJ, USA] or isotype control rabbit IgGs against rabies virus nu-
cleoprotein [43]) diluted in phosphate-buffered saline (PBS) with 10% normal goat serum (NGS) and
Alexa Fluor 647-conjugated secondary antibody (Thermo Fisher Scientific). Particles were washed 3
times with PBS for 5min per wash prior to and after secondary antibody staining.
Viral growth kinetics in PK15 cells and SCG neurons. For immunofluorescence staining of
infected PK15 cells and dissociated SCGs, cells were fixed in methanol at 220°C for 20min at the indi-
cated times after infection. Primary antibodies (rabbit polyclonal anti-UL13, rabbit polyclonal anti-VP16,
rabbit polyclonal anti-VP26, mouse monoclonal anti-Us3, and isotype controls [44]) were diluted in 10%
NGS-PBS and added to cells for 1 h at 37°C followed by incubation of 1 h at 37°C with Alexa Fluor 488
(green)-, 594 (red)-, or 647 (magenta)-conjugated secondary antibodies. During the last 10min of sec-
ondary antibody staining, DAPI (49,6-diamidino-2-phenylindole) was added to cells to stain cell nuclei.
Chambered SCG neurons. For immunofluorescence staining of chambered SCGs during virus traf-
ficking experiments, cells were fixed in 1% paraformaldehyde (PFA) at room temperature (RT) for 10min,
permeabilized in 0.1% Triton X-100 for 2min at RT. Staining was performed with primary polyclonal rab-
bit anti-eGFP antibodies (Invitrogen) or isotype control antibodies and secondary Alexa Fluor 488-conju-
gated antibodies, as described above.
Live-cell imaging. All imaging was done using a previously described Nikon Ti-E inverted epifluores-
cence microscope (45).
Virus particle trafficking. Virus particle trafficking was assessed using live-cell imaging as described
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previously (46). Briefly, chambered SCGs grown onto Ibidi glass dishes were placed inside a stage top in-
cubator system at 37°C and 5% (vol/vol) CO2 (Live Cell Instrument/Quorum Scientific), prior to inocula-
tion with 106 PFU of virus. Movies were acquired either with phase, green, red, or cyan fluorescence fil-
ters using a 60 Plan Fluor Ph3 objective (Nikon) and an iXon 895 back-thinned electron multiplying
charge-coupled device (EM-CCD) camera (Andor, Belfast, Northern Ireland). The imaging window was
maintained at a fixed height of 100 pixels and a width of 300 pixels. The fluorescence exposure was set
to 200ms, with the EM Gain filter set to 300. The acquisition rate was approximately 4 frames per sec-
ond, on average. For the dual fluorescent movies, the exposure was set to 300ms and the acquisition
rate was approximately 1 frame per second. Movies were created and virus particles were manually
tracked in infected axons using ImageJ software (National Institutes of Health, Bethesda, MD, USA).
Escape from silencing. Escape from silencing was assessed on tiled images of the entire S compart-
ment. These images were captured using the Nikon NIS Elements software, a Cool Snap ES2 camera
(Photometrics), and a 4 magnification objective (Nikon). Color thresholds were set manually, prior to
converting images to 8-bit gray-scale images using ImageJ. Next, the relative amount of red fluores-
cence (viral production) was divided by the amount of green fluorescence (only those neurons that pro-
ject their axons to the N compartment) to determine the percentage of susceptible neurons that
escaped from silencing. Since the majority of neurons sent axons through the N compartment (.90%),
only the percentage of red fluorescence was monitored (viral production) upon AAV inoculation.
Colocalization image analysis. Colocalization of red (capsids) and green/cyan (UL13/VP16) puncta
was verified by image analysis using ImageJ. Briefly, RGB images were converted to 8-bit images and
subjected to conservative thresholding. Next, binary image multiplication was used to determine the
overlap of puncta. The results of 5 microscopic fields were added to obtain a total value.
Colocalization of UL13 with eGFP, and VP16 with mTurquoise, respectively, in infected cells was veri-
fied by image analysis using ImageJ. Briefly, RGB images were converted to 8-bit images. Next, binary
image subtraction was used to determine the overlap of colors.
Western blot analysis. Virion protein content of newly constructed PRV mutants was characterized
by Western blotting. For this, 1012 genome copies of purified virus stocks were mixed with 5 Laemmli
buffer and heated at 95°C for 5min. Samples were then loaded onto 10% NuPAGE BisTris gels
(Invitrogen) and run for 15min at 100V and 45min at 200V in MOPS (morpholinepropanesulfonic acid)
buffer. Proteins were transferred to nitrocellulose membranes using semidry transfer at 18V for 90min.
Next, membranes were washed 2 times with ultrapure water for 2min and incubated in antigen pre-
treatment solution (Invitrogen) for 10min at RT. After 5 rinses with ultrapure water, membranes were
incubated in 5% nonfat dry milk in phosphate-buffered saline supplemented with 0.1% Tween 20 (PBST)
solution for 1 h at RT. Following three 5-min washing steps in PBST, membranes were stained with pri-
mary antibodies diluted 1:1,000 in primary antibody diluent (Invitrogen) overnight at 4°C. Secondary
antibodies (goat anti-mouse or anti-rabbit antibodies conjugated to horseradish peroxidase [HRP]
[Thermo Fisher Scientific]) were diluted 1:20,000 in 1% milk-PBST solution and added to the membranes
for 30min at RT after and prior to a thorough washing step (4 times 5min washing in PBST). Membranes
were incubated with chemiluminescent substrates (Supersignal Dura, Thermo Fisher scientific). Protein
bands were visualized by exposure on HyBlot CL (Denville Scientific) blue X-ray films. Primary antibodies
used for Western blot were anti-VP5 mouse monoclonal antibody (MAb) (gift of H. J. Rziha, Federal
Research Center for Viruses Diseases for Animals, Tubingen, Germany), anti-Us3 mouse MAb (44), and
anti-UL13 polyclonal rabbit sera (produced in-house). VP5 (capsid) protein functioned as an internal
loading control to determine the relative amount of proteins present in different purified virus stocks.
This was determined through plot profiling in ImageJ.
Statistical analyses. Significant differences (P, 0.05) between different CRISPR gene editing meth-
ods or between mock-inoculated and different PRV mutant-inoculated cells were identified by analysis
of variance (ANOVA) followed by a Tukey post hoc test. If homoscedasticity of the variables was not met,
as assessed by Levene’s test, the data were log transformed prior to ANOVA. The normality of the resid-
uals was verified using the Shapiro-Wilk test. If the variables remained heteroscedastic or normality was
not met after log transformation, a Kruskal-Wallis test followed by a Mann-Whitney post hoc test were
performed. All analyses were conducted in IBM SPSS Statistics for Windows, version 25.0 (IBM Corp.,
Armonk, NY, USA).
Ethics statement. All animal work was performed in accordance with the Princeton Institutional
Animal Care and Use Committee (protocols 1947–16). Princeton personnel are required to adhere to ap-
plicable federal, state, local, and institutional laws and policies governing animal research, including the
Animal Welfare Act and Regulations (AWA), the Public Health Service Policy on Humane Care and Use of
Laboratory Animals, the Principles for the Utilization and Care of Vertebrate Animals Used in Testing,
Research and Training, and the Health Research Extension Act of 1985.
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